A Phase I Clinical Trial to Determine the Safety and Tolerability of UC-961 (Cirmtuzumab), an Anti-ROR1 Monoclonal Antibody, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Are Ineligible for Chemotherapy

Trial Profile

A Phase I Clinical Trial to Determine the Safety and Tolerability of UC-961 (Cirmtuzumab), an Anti-ROR1 Monoclonal Antibody, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Are Ineligible for Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Cirmtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 13 Dec 2016 New trial record
    • 06 Dec 2016 Interim results (n=20) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Early data from this study presented at the 58th Annual Meeting of the American Society of Hematology (ASH), as per an Oncternal Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top